Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.

Toprani A, Fonseca V.

Diabetes Obes Metab. 2011 Mar;13(3):276-80. doi: 10.1111/j.1463-1326.2010.01348.x. Erratum in: Diabetes Obes Metab. 2012 Apr;14(4):386.

PMID:
21205120
2.

Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.

Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Erratum in: Clin Ther. 2012 Feb;34(2):508. Chou, Chih-Chieh [corrected to Chou, Chin-Chieh].

PMID:
22118894
4.

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study.

Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS.

Diabetes Care. 2003 Nov;26(11):2983-9.

PMID:
14578227
5.

Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.

Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.

Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679. Epub 2013 Sep 11.

PMID:
24029780
6.

Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.

Granberry MC, Hawkins JB, Franks AM.

Am J Health Syst Pharm. 2007 May 1;64(9):931-6. Review.

PMID:
17468147
7.
8.

Pioglitazone initiation and subsequent hospitalization for congestive heart failure.

Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM.

Diabet Med. 2005 Aug;22(8):986-93.

9.

Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality.

Roussel R, Hadjadj S, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Tubach F, Marre M, Porath A, Krempf M, Bhatt DL, Steg PG.

Int J Cardiol. 2013 Aug 20;167(4):1380-4. doi: 10.1016/j.ijcard.2012.04.019. Epub 2012 May 4.

PMID:
22560911
10.

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.

PMID:
20110009
11.

Considerations for management of fluid dynamic issues associated with thiazolidinediones.

Hollenberg NK.

Am J Med. 2003 Dec 8;115 Suppl 8A:111S-115S. Review.

PMID:
14678876
12.

Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.

Rascati KL, Richards KM, Lopez D, Cheng LI, Wilson JP.

Clin Ther. 2011 Dec;33(12):2016-20. doi: 10.1016/j.clinthera.2011.10.018. Epub 2011 Nov 21.

PMID:
22101160
13.

The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.

Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):504-12.

PMID:
17245800
14.

Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin.

Marceille JR, Goins JA, Soni R, Biery JC, Lee TA.

Pharmacotherapy. 2004 Oct;24(10):1317-22.

PMID:
15628829
15.

Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?

Buckingham RE, Hanna A.

Diabetes Obes Metab. 2008 Apr;10(4):312-28. doi: 10.1111/j.1463-1326.2006.00700.x. Review.

PMID:
18333890
16.

Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.

Rascati K, Richards K, Lopez D, Cheng LI, Wilson J.

Diabetes Obes Metab. 2013 Oct;15(10):901-5. doi: 10.1111/dom.12103. Epub 2013 Apr 18.

PMID:
23531154
17.

Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.

Hernandez AV, Usmani A, Rajamanickam A, Moheet A.

Am J Cardiovasc Drugs. 2011;11(2):115-28. doi: 10.2165/11587580-000000000-00000. Review.

PMID:
21294599
18.

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5.

PMID:
19194648
19.

Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.

Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM.

Diabetes Care. 2005 Jul;28(7):1680-9.

PMID:
15983320
20.

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.

Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM.

Circulation. 2005 Feb 8;111(5):583-90.

Supplemental Content

Support Center